Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1975 10
1976 12
1977 5
1978 14
1979 9
1980 6
1981 8
1982 12
1983 11
1984 8
1985 18
1986 10
1987 11
1988 25
1989 12
1990 17
1991 7
1992 10
1993 6
1994 10
1995 7
1996 8
1997 6
1998 1
1999 7
2000 1
2001 13
2002 3
2003 9
2004 9
2005 10
2006 16
2007 6
2008 16
2009 12
2010 10
2011 14
2012 19
2013 11
2014 7
2015 8
2016 8
2017 7
2018 7
2019 14
2020 10
2021 1
2022 15
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.
Pace E, Cerveri I, Lacedonia D, Paone G, Sanduzzi Zamparelli A, Sorbo R, Allegretti M, Lanata L, Scaglione F. Pace E, et al. Pharmaceutics. 2022 Jun 14;14(6):1261. doi: 10.3390/pharmaceutics14061261. Pharmaceutics. 2022. PMID: 35745833 Free PMC article. Review.
In the present review, 72 articles, published in peer-reviewed journals with high impact factors, are analyzed in order to provide significant insight and increase the knowledge about COPD considering the important contribution of carbocysteine in reducing exacerbations vi …
In the present review, 72 articles, published in peer-reviewed journals with high impact factors, are analyzed in order to provide significa …
Oxidative stress-based therapeutics in COPD.
Barnes PJ. Barnes PJ. Redox Biol. 2020 Jun;33:101544. doi: 10.1016/j.redox.2020.101544. Epub 2020 Apr 20. Redox Biol. 2020. PMID: 32336666 Free PMC article. Review.
Most clinical studies in COPD have been conducted using glutathione-generating antioxidants such as N-acetylcysteine, carbocysteine and erdosteine, which reduce exacerbations in COPD patients, but it is not certain whether this is due to their antioxidant or mucolytic prop …
Most clinical studies in COPD have been conducted using glutathione-generating antioxidants such as N-acetylcysteine, carbocysteine a …
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Rogliani P, et al. Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y. Respir Res. 2019. PMID: 31133026 Free PMC article.
METHODS: A pairwise and network meta-analyses were performed to assess the efficacy of erdosteine, carbocysteine, and NAC on acute exacerbation of COPD (AECOPD), duration of AECOPD, and hospitalization. ...Erdosteine and NAC both significantly reduced the duration of AECOP …
METHODS: A pairwise and network meta-analyses were performed to assess the efficacy of erdosteine, carbocysteine, and NAC on acute ex …
S-carboxymethyl-L-cysteine.
Mitchell SC, Steventon GB. Mitchell SC, et al. Drug Metab Rev. 2012 May;44(2):129-47. doi: 10.3109/03602532.2011.631015. Drug Metab Rev. 2012. PMID: 22497630 Review.
Carbocysteine.
Brown DT. Brown DT. Drug Intell Clin Pharm. 1988 Jul-Aug;22(7-8):603-8. doi: 10.1177/106002808802200721. Drug Intell Clin Pharm. 1988. PMID: 3046890 Review.
Carbocysteine is prescribed for conditions characterized by the accumulation of excessive mucus. ...The chemistry, pharmacology, pharmacokinetics, clinical applications, and toxicology of carbocysteine are reviewed....
Carbocysteine is prescribed for conditions characterized by the accumulation of excessive mucus. ...The chemistry, pharmacology, phar …
Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy.
Bianco A, Conte S, Mariniello DF, Allocca V, Matera MG, D'Agnano V, Lanata L, Cazzola M, Perrotta F. Bianco A, et al. Life (Basel). 2022 Nov 8;12(11):1824. doi: 10.3390/life12111824. Life (Basel). 2022. PMID: 36362979 Free PMC article. Review.
SARS-CoV-2 infection leads to a heterogenous spectrum of clinical conditions ranging from self-limiting upper airway infection to severe respiratory failure. Carbocysteine is a thioether mucolytic with antioxidant and anti-inflammatory activities. ...In this review, we exp …
SARS-CoV-2 infection leads to a heterogenous spectrum of clinical conditions ranging from self-limiting upper airway infection to severe res …
Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases.
Macciò A, Madeddu C, Panzone F, Mantovani G. Macciò A, et al. Expert Opin Pharmacother. 2009 Mar;10(4):693-703. doi: 10.1517/14656560902758343. Expert Opin Pharmacother. 2009. PMID: 19239402 Review.
BACKGROUND: Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. ...Moreover, carbocysteine was effective in counteracting some symptoms associated with cancer cachexia. ...
BACKGROUND: Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. ...Moreover, carboc …
Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnea Syndrome: A Randomized Clinical Trial.
Wu K, Su X, Li G, Zhang N. Wu K, et al. PLoS One. 2016 Feb 5;11(2):e0148519. doi: 10.1371/journal.pone.0148519. eCollection 2016. PLoS One. 2016. PMID: 26849119 Free PMC article. Clinical Trial.
Endothelial function was assessed with ultrasound in the carbocysteine group. RESULTS: The proportion of patients who fulfilled the criteria for good compliance was higher in the carbocysteine group (n = 17) than in the CPAP group (n = 11; 100% vs. 64.7%). ...Car …
Endothelial function was assessed with ultrasound in the carbocysteine group. RESULTS: The proportion of patients who fulfilled the c …
Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease.
Chalumeau M, Duijvestijn YC. Chalumeau M, et al. Cochrane Database Syst Rev. 2013 May 31;(5):CD003124. doi: 10.1002/14651858.CD003124.pub4. Cochrane Database Syst Rev. 2013. PMID: 23728642 Review.
BACKGROUND: Acetylcysteine and carbocysteine are the most commonly prescribed mucolytic drugs in Brazil and many European and African countries. ...SELECTION CRITERIA: To study efficacy, we used randomised controlled trials (RCTs) comparing the use of acetylcysteine or …
BACKGROUND: Acetylcysteine and carbocysteine are the most commonly prescribed mucolytic drugs in Brazil and many European and African …
Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study.
Ferraro M, Di Vincenzo S, Sangiorgi C, Leto Barone S, Gangemi S, Lanata L, Pace E. Ferraro M, et al. Pharmaceuticals (Basel). 2022 Feb 11;15(2):218. doi: 10.3390/ph15020218. Pharmaceuticals (Basel). 2022. PMID: 35215330 Free PMC article.
The in vivo effects of carbocysteine on inflammatory markers are not yet fully understood. The aims of this study were to assess: (i) miR-21, IL-8, soluble Receptor for Advanced Glycation End Products (sRAGE), and fluorescent Advanced Glycation End Products (fAGEs) in cont …
The in vivo effects of carbocysteine on inflammatory markers are not yet fully understood. The aims of this study were to assess: (i) …
455 results